First Affiliated Hospital Xi'an Jiaotong University
Phase
Observational
Started
2024-12-31
Last updated
2024-04-04
Condition(s) studied
Atrial FibrillationIntracardiac Thrombus
Investigational drug(s) / intervention(s)
Observational; No Interventions were given.
Observational; No Interventions were given.: Observational; No Interventions were given.
Study summary
This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years old, age ≤80 years old
* Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter
* Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy
Exclusion Criteria:
* Echocardiography confirmed valvular heart disease
* Contraindications to anticoagulants
* Patients with the previous history of hemorrhagic stroke
* Low platelet count or functional platelet defects
* Congenital or acquired coagulation or bleeding disorders
* Abnormal liver function (liver enzymes \>2 times the upper limit)
* Renal failure (endogenous creatinine clearance \<30ml/min)
* Surgery was planned within the intended study time or had been operated within 30 days before the study
* Other comorbidities that can cause bleeding, such as tumors
* Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators
* Patients are currently participating in other clinical studies
Primary outcome measure(s)
Success rate of thrombolysis — 1,2,3 months after enrollment. Success rate of thrombolysis within 3 months after initiating anticoagulation therapy.
Change of incidence of MACCE — 1,2,3 months after enrollment. Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, coronary revascularization, and stroke.
Trial sites (1)
Facility
City
Region
Status
First Affiliated Hospital of Xian Jiantong University
Xi'an
Shaanxi
More First Affiliated Hospital Xi'an Jiaotong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.